Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxie
Moderna (MRNA), Vaxcyte (PCVX), and Novavax (NVAX) stocks moved in after-hours trading on Monday. Moderna rose 0.17% to $203.56, while Novavax and Vaxcyte fell 0.88% and 4.36% respectively. The movement followed a suspected pneumonic plague case in Russia. Vaxcyte announced a $1 billion raise to fund trials and manufacturing. Moderna's COO returned to lead a new launch with Merck (MRK).
How this was made
The 30-second read
Why it matters
The combined health‑event and financing news create mixed short‑term signals for vaccine makers, with potential longer‑term upside for Vaxcyte's pipeline.
Market read
Short‑term price moves driven by health‑event risk and a large capital raise; sector sentiment may stay cautious.
What to watch
Vaxcyte's capital raise positions it to accelerate its VAX‑31 program, which could offset short‑term dilution concerns.
Background
A suspected pneumonic plague case in Russia sparked sector‑wide movement in vaccine stocks, while Vaxcyte disclosed a $1 B financing package.
Ticker impact
Moderna shares rose modestly in after‑hours trading after news of a suspected pneumonic plague case in Russia and the appointment of a new COO.
modest upside as market prices in the news
The stock already moved up in regular session; after‑hours move is small and driven by a single event, so impact is limited.
Vaxcyte fell 4.36% in after‑hours trading despite announcing a $1 billion capital raise (stock and warrants plus convertible notes).
likely pressure as investors digest dilution
A $1 B raise is material; the immediate price drop reflects market concern over dilution and debt issuance.
Novavax slipped 0.88% in after‑hours trading following the same pneumonic plague news that moved other vaccine stocks.
slight pressure as investors reassess exposure
The move is small and tied to broader sector sentiment rather than a company‑specific catalyst.
Market effects
Vaccine sector faces heightened risk perception due to the Russian plague case, potentially weighing on related stocks.
Limited to U.S. biotech and vaccine equities; no broader market effect noted.
Minor, as the event is localized and does not affect global macro indicators.
Counterpoint
The plague news may be over‑reacted to; vaccine companies could benefit from increased demand for prophylactics.
Key entities
- companyModerna Inc.
US biotech developing mRNA vaccines.
- companyVaxcyte Inc.
Biotech focused on pneumococcal conjugate vaccines.
- companyNovavax Inc.
Vaccine developer.
